NovaBay Pharmaceuticals, Inc. (NBY)

Market Cap	2.78M
Revenue (ttm)	14.73M
Net Income (ttm)	-16.70M
Shares Out	36.06M
EPS (ttm)	-3.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,564,470
Open	0.0703
Previous Close	0.0725
Day's Range	0.0680 - 0.0791
52-Week Range	0.0680 - 1.4200
Beta	2.01
Analysts	n/a
Price Target	n/a
Earnings Date	May 9, 2024

About NBY

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 26, 2007
• Employees: 24
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: NBY

Financial Performance

In 2023, NBY's revenue was $14.73 million, an increase of 2.24% compared to the previous year's $14.40 million. Losses were -$16.70 million, 2.66% more than in 2022.